On-treatment monitoring of chronic hepatitis B virus infection: An Asian-Pacific perspective

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 852-857

  Chien, Rong Nan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Asia Pacific region; Drug resistant HBV; Hepatitis B virus; Nucleos(t)ide analogues; On treatment monitoring

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; NUCLEOSIDE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; TENOFOVIR; THYMIDINE; ADEFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASIA; CHRONIC HEPATITIS; CHRONIC HEPATITIS B VIRUS INFECTION; CLINICAL TRIAL; DISEASE COURSE; DNA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENOTYPE; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; IMMUNOPATHOGENESIS; LONG TERM CARE; LOWEST INCOME GROUP; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL CARE; MONITORING; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PACIFIC ISLANDS; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POLYMERIZATION; POPULATION; PREDICTION; PREDICTION AND FORECASTING; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; THERAPY EFFECT; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; DRUG MONITORING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B, CHRONIC; PROCEDURES; TIME; ASIAN; CHRONIC HEPATITIS B; CLINICAL TRIAL (TOPIC); HISTOPATHOLOGY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MONOTHERAPY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; ASIA; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG MONITORING; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; ORGANOPHOSPHONATES; PYRIMIDINONES; THYMIDINE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 77951752202     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06271.x     Document Type: Review

References (35)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009 373 : 582 592.
2. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am. J. Med. 2004 116 : 829 834.
3. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007 45 : 1187 1192.
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 2008 48 : 335 352.
5. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009 29 (Suppl. 1 100 107.
6. Tan AT, Koh S, Goh V, Bertoletti A. Understanding the immunopathogenesis of chronic hepatitis B: an Asian prospective. J. Gastroenterol. Hepatol. 2008 23 : 833 843.
7. Zoulim F, Perrillo R, Hepatitis B. Reflection on the current approach to antiviral therapy. J. Hepatol. 2008 48 : S2 S19.
8. Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res. Clin. Gastroenterol. 2008 22 : 1081 1092.
9. Liaw YF, Leung N, Kao JH et al. Asian-Pacific Consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008 2 : 263 283.
10. Liaw YF. Advancing the clinical treatment of hepatitis B virus in the Asian-Pacific region. Liver Int. 2006 26 : 1 58.
11. Chien RN. The therapeutic guideline of patients with chronic hepatitis B in Taiwan. Gastrointestinal J. Taiwan 2008 25 : S9 S23.
12. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J. Hepatol. 2007 46 : 45 52.
13. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004 351 : 1521 1531.
14. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 117.
15. Gauthier J, Bourne EJ, Lutz MW et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J. Infect. Dis. 1999 180 : 1757 1762.
16. Lai CL, Leung N, Teo EK et al. A 1 year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 129 : 528 536. (Pubitemid 41096641)
17. Lai CL, Gane E, Liaw YF et al. A comparison of telbivudine and lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007 357 : 34 46.
18. Liaw YF, Gane E, Leung N et al. 2 year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009 136 : 486 495.
19. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5 year ideal response. Hepatology 2007 46 : 1695 1703.
20. Hadziyannis AS, Mitsoula PV, Hadziyannis SJ. Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg-negative chronic hepatitis B. Hepatology 2007 46 (Suppl. 1 667A.
21. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001 34 : 785 791.
22. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 1751.
23. Chan HL, Heathcote EJ, Marcellin P et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 2007 147 : 745 754.
24. Gallego A, Sheldon J, Garcia-Samaniego J et al. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J. Viral Hepat. 2008 15 : 392 398.
25. Locarnini S, Qi X, Arterburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J. Hepatol. 2005 42 (Suppl. 2 17.
26. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 133 : 1437 1444.
27. Lai CL, Gane E, Liaw YF et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1011 1020.
28. Entecavir (BMS-200475) Antiviral Drugs Advisory Committee (AVDAC) briefing document Cited 5 April 2009.] Available from URL: http://www.fda.gov/ ohrms/dockets/ac/05/briefing/2005-4094B1-01-BristolMyersSquibb-entecavir.pdf
29. Zeuzem S, Gane E, Liaw YF et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J. Hepatol. 2009 51 : 11 20.
30. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008 259 : 2442 2455.
31. Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir. Ther. (Lond.) 2009 14 : 13 22.
32. Keeffe EB, Dieterich DT, Han SB et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gasatroenterol. Hepatol. 2008 6 : 1315 1341.
33. Lampertico P, Vigano M, Manenti E et al. Low resistance to adefovir combined with lamivudine: a 3 year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 : 1445 1451.
34. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007 46 : 254 265.
35. Chien RN, Liaw YF. Current treatment of Chronic HBV infection: an Asian-Pacific perspective. Curr. Hepatitis. Rep. 2009 8 : 154 160.